We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nano Labs Ltd | NASDAQ:NA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 1.81% | 8.42 | 8.01 | 8.99 | 9.00 | 7.87 | 7.87 | 10,450 | 22:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number: 001-41426
Nano Labs Ltd
(Exact name of registrant as specified in its charter)
China Yuangu Hanggang Technology Building
509 Qianjiang Road, Shangcheng District,
Hangzhou, Zhejiang, 310000
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Interim Condensed Balance Sheet as of September 30, 2024
Nano Labs Ltd (the “Company”) sets forth the preliminary unaudited condensed balance sheet as of September 30, 2024, which have been prepared by, and are the responsibility of, the Company’s management. The preliminary financial data are based on the information currently available to us as of the date of this report.
Nano Labs Ltd
Consolidated Balance Sheets
(Unaudited)
As of Sept 30, | As of Sept 30, | |||||||
2024 | 2024 | |||||||
RMB | US$* | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | 50,322,415 | 7,181,325 | ||||||
Restricted cash | 418,201 | 59,680 | ||||||
Accounts receivable, net | 2,178,747 | 310,921 | ||||||
Inventories, net | 10,191,230 | 1,454,353 | ||||||
Prepayments | 24,155,244 | 3,447,105 | ||||||
Other current assets | 52,524,971 | 7,495,643 | ||||||
Total current assets | 139,790,808 | 19,949,026 | ||||||
Non-current assets: | ||||||||
Property, plant and equipment, net | 197,476,913 | 28,181,196 | ||||||
Intangible asset, net | 46,991,905 | 6,706,040 | ||||||
Operating lease right-of-use assets | 7,028,136 | 1,002,959 | ||||||
Total non-current assets | 251,496,954 | 35,890,195 | ||||||
TOTAL ASSETS | 391,287,762 | 55,839,222 | ||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Short-term debts | 20,000,000 | 2,854,126 | ||||||
Current portion of long-term debts | 4,580,000 | 653,595 | ||||||
Accounts payable | 12,481,588 | 1,781,201 | ||||||
Advance from customers | 83,505,919 | 11,916,819 | ||||||
Operating lease liabilities, current | 2,877,067 | 410,576 | ||||||
Other current liabilities | 70,839,217 | 10,109,201 | ||||||
Total current liabilities | 194,283,792 | 27,725,518 | ||||||
Non-current liabilities: | ||||||||
Long-term debts | 169,833,636 | 24,236,327 | ||||||
Operating lease liabilities, non-current | 3,938,711 | 562,079 | ||||||
Total non-current liabilities | 173,772,347 | 24,798,406 | ||||||
Total liabilities | 368,056,139 | 52,523,923 | ||||||
Shareholders' equity : | ||||||||
Class A ordinary shares | 100,584 | 14,354 | ||||||
Class B ordinary shares | 36,894 | 5,265 | ||||||
Additional paid-in capital | 531,220,288 | 75,808,472 | ||||||
Accumulated deficit | (519,783,722 | ) | (74,176,402 | ) | ||||
Statutory reserves | 6,647,109 | 948,584 | ||||||
Accumulated other comprehensive income | 5,010,470 | 715,026 | ||||||
Total Nano Labs Ltd shareholders' equity | 18,516,603 | 2,642,436 | ||||||
Noncontrolling interests | 4,715,020 | 672,863 | ||||||
Total shareholders' equity | 23,231,623 | 3,315,299 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 391,287,762 | 55,839,222 |
* | Convenient translation rate is US$1 = RMB7.0074 |
1
In accordance with Nasdaq Listing Rule 5550(b)(1), the Company is required to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market. Based on the financial statements for the six months ended/as of June 30, 2024, as disclosed by the Company on September 18, 2024, the Company had fallen below this requirement.
During the three months ended September 30, 2024, the Company entered into agreements with Mr. Jianping Kong, its chairman and chief executive officer, and Mr. Qifeng Sun, its vice chairman, along with their respective affiliates (the “Lenders”) on September 20, 2024, to convert the interest-free loans from the Lenders in an aggregated amount of US$8.5 million into certain amount of Class A ordinary shares (the “Conversion”) in lieu of repayment of the Loans. The Conversion has been closed on September 23, 2024. This transaction has strengthened the Company’s financial position and increased its stockholders’ equity. As of the date the Company furnished this report, the Company reasonably believes it is compliant with Nasdaq Capital Market’s minimum stockholders' equity requirement of $2.5 million as a result of the aforementioned transaction.
The Company acknowledges that Nasdaq will continue to monitor its ongoing compliance with the stockholders’ equity requirement. If at the time of its next periodic report the Company does not evidence compliance with this requirement, it may be subject to delisting from The Nasdaq Capital Market.
This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, as amended, initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2023 (Registration No. 333-273968) and a prospectus supplement dated April 11, 2024 thereunder, and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
Forward-Looking Statements
This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s compliance with the relevant Nasdaq continued listing standards, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s compliance status, actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Nano Labs Ltd | ||
Date: November 21, 2024 | By: | /s/ Jianping Kong |
Name: | Jianping Kong | |
Title: | Chairman and Chief Executive Officer |
3
1 Year Nano Labs Chart |
1 Month Nano Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions